Unresectable Gastric Cancer Achieving pCR Via Conversion Surgery after Chemotherapy-Implications for Optimizing Individualized Treatment (PubMed, Gan To Kagaku Ryoho) - Sep 12, 2026 - "Consequently, 2 courses of SOX plus nivolumab were administered...The postoperative course was uneventful and there were no major complications. At 5 months postoperatively, no recurrence was detected and SOX chemotherapy is currently being administered as postoperative adjuvant therapy."
Journal • Gastric Cancer • Oncology • Solid Tumor • CLDN18 • HER-2 • PD-L1
|
|
Fuka Fujimoto; Haruka Kirihara; Hiroyuki Sagawa; Kaori Watanabe; Kazuyoshi Shiga; Naoi Sato; Ryo Nakajima; Shigeyuki Kosaka; Shinnosuke Harata; Shuji Takiguch; Tatsuya Tanaka; Tomoya Shamoto; Yoichi Matsuo
|